In the setting of breast cancer, however, obesity is associated with reduced efficacy of aromatase inhibitors.180 This observation may be explained in part by increased expression of aromatase in the breast due to obesity-related adipose tissue inflammation, which will be discussed below. Here, CYP19A1 is linked to breast cancer.